RSNA 2008 Annual Meeting In Brief
Hologic's tomosynthesis: New data presented at Radiological Society of North America conference in Chicago on Dec. 2 shows Hologics' tomosynthesis breast mammography system Selenia Dimensions has a lower recall rate than traditional mammography and can detect tumors in dense breasts. The Selenia Dimensions takes a series of images to show tissue structure in three dimensions, allowing physicians to see an anomaly in breast tissue from multiple angles. Hologic originally expected FDA to approve the PMA for Selenia Dimensions in the second quarter of 2008, but FDA approval for the device was pushed back by a July 30 letter from the agency, requesting additional information (1"The Gray Sheet" Jan. 21, 2008, p. 7). FDA will likely convene an advisory panel meeting to review the PMA. Selenia Dimensions received a CE mark in Europe during the firm's fourth fiscal quarter of 2008. "We continue to see approval as when, not if," Morgan Stanley analyst David Lewis writes in a Dec. 4 report on tomosynthesis. "Focus will eventually turn to the technology, which has garnered considerable physician interest as a revolution versus digital, although concerns on adoption, workflow and applicable market exist.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?
Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.
A change of government, hospital reform and a drive towards healthcare digitization are keeping German medtech manufacturers on their toes. Making the MDR more user-friendly and winning support for a medtech strategy are arguably bigger priorities. US export tariffs have also pushed their way onto the agenda. BVMed chief executive Marc-Pierre Möll puts it all into context.